首页 / 院系成果 / 成果详情页

Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China 期刊论文

编号：

39bead94-a514-4b06-8e7b-5cde81f2dc8d
作者：

Gong, Dan#^[1,2]Li, Wei(李薇)#^[3]Hu, LiangDing#^[4]Shen, JianLiang^[5];Fang, MeiYun^[6];Yang, QingMing^[7];Wang, HengXiang^[8];Ke, XiaoYan^[9];Chen, HuiRen^[10];Wang, Zhao^[11];Liu, Hui^[12];Liu, Feng^[13];Ma, YiGai^[14];Wang, JingWen^[15];Li, HongHua^[1];Wang, QuanShun^[1];Jing, Yu^[1];Gao, XiaoNing^[1];Dou, LiPing^[1];Li, YongHui^[1];Luo, JianMin(罗建民)*^[16]Yu, Li(于力)*^[1]
语种：

English
期刊：

ACTA HAEMATOLOGICA ISSN：0001-5792 2016 年 136 卷 4 期 (201 - 209)
收录：
关键词：

Acute myeloid leukemia Consolidation therapy Cytarabine RUNX1/RUNX1T1
摘要：

Background: The survival of patients with acute myeloid leukemia (AML) with t(8;21) was reported to be shorter in China than in other countries. Patients: We analyzed the correlation between different cytarabine (Ara-c) regimens and outcome in 255 t(8;21) AML patients in China who received postremission consolidation chemotherapy only. Results: The 5-year overall survival (OS) of the high-dose Ara-c group (HDAC; 2 <= Ara-c g/m(2)), intermediate-dose Ara-c group (MDAC; 1.0 <= Ara-c <2.0 g/m(2)), low-dose Ara-c group (LDAC; 0.2< Ara-c <1.0 g/m(2)) and standard-dose Ara-c group (SDAC; 0.1 <= Ara-c <= 0.2 g/m(2)) were 65.3, 39.4, 25.2 and 27.9%, respectively (p = 0.003). In the HDAC group, but not in the MDAC group, the 5-year OS of patients who achieved 3-4 cycles of chemotherapy was superior to those who underwent 1-2 cycles (84.4 vs. 43.6%, p < 0.05), and the 3-year OS of patients who achieved an accumulated 36 g/m(2) of Ara-c was significantly higher compared to those who did not (85.3 vs. 39.2%, p < 0.05). Multivariate analysis indicated that factors such as WBC >3.5 x 10(9)/l, PLT x 10(9)/l, and extra medullary infiltration were associated with a poor prognosis. Conclusion: The survival of t(8;21) AML patients treated with high-dose Ara-c (>= 2 g/m(2)) was superior to other dose levels in postremission consolidation chemotherapy. Patient survival was improved by 3-4 cycles of chemotherapy with an accumulated concentration of 36 g/m(2) of Ara-c. WBC >3.5 x 10(9)/l, PLT <= 30 x 10(9)/l and extramedullary infiltration could be indicative of a poor clinical prognosis. (C) 2016 S. Karger AG, Basel
推荐引用方式
GB/T 7714：

Gong Dan,Li Wei,Hu Liang-Ding, et al. Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China [J].ACTA HAEMATOLOGICA,2016,136(4):201-209.
APA：

Gong Dan,Li Wei,Hu Liang-Ding,Shen Jian-Liang,&Yu Li.(2016).Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China .ACTA HAEMATOLOGICA,136(4):201-209.
MLA：

Gong Dan, et al. "Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China" .ACTA HAEMATOLOGICA 136,4(2016):201-209.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：50  下载次数：0

分享到：

浏览次数：50

下载次数：0

打印次数：0